Summary: Centessa Prescription drugs has received Food and drug administration authorization to commence a section 1 demo of ORX750, an investigational oral therapy aimed at narcolepsy and other slumber-wake conditions. ORX750, a selective orexin receptor 2 agonist, addresses the … [Read more...]
Zevra Highlights Plans to Advance IH, Narcolepsy Drug Candidate
Summary: Zevra Therapeutics Inc., in its yr-conclude fiscal and corporate update for 2023, highlighted the development of KP1077 in dealing with idiopathic hypersomnia, citing promising Stage 2 analyze final results. The organization also introduced designs to existing new info … [Read more...]
Zevra Reports Positive Phase 2 Results for IH Drug Candidate
Summary: The stage 2 scientific trial of KP1077 by Zevra Therapeutics for treating idiopathic hypersomnia (IH) has yielded good leading-line effects, confirming the drug’s security and tolerability. KP1077 demonstrated important enhancements in indications these as too much … [Read more...]